Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pharmacoepidemiology | 19 | 2022 | 323 | 4.220 |
Why?
|
Product Surveillance, Postmarketing | 19 | 2021 | 430 | 4.070 |
Why?
|
Angioedema | 8 | 2023 | 187 | 3.040 |
Why?
|
Confidentiality | 10 | 2023 | 612 | 3.010 |
Why?
|
Multicenter Studies as Topic | 9 | 2023 | 1677 | 2.860 |
Why?
|
United States Food and Drug Administration | 31 | 2023 | 1584 | 2.210 |
Why?
|
Research Design | 19 | 2023 | 5984 | 2.000 |
Why?
|
Databases, Factual | 39 | 2022 | 7730 | 1.950 |
Why?
|
Privacy | 6 | 2023 | 238 | 1.940 |
Why?
|
Comparative Effectiveness Research | 9 | 2018 | 680 | 1.860 |
Why?
|
Information Dissemination | 5 | 2020 | 1099 | 1.840 |
Why?
|
International Classification of Diseases | 15 | 2022 | 867 | 1.750 |
Why?
|
Computer Security | 5 | 2023 | 262 | 1.630 |
Why?
|
Propensity Score | 17 | 2022 | 1781 | 1.620 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 8 | 2023 | 1516 | 1.490 |
Why?
|
Clinical Coding | 5 | 2021 | 171 | 1.470 |
Why?
|
Fluoroquinolones | 2 | 2023 | 310 | 1.450 |
Why?
|
Epidemiologic Research Design | 5 | 2019 | 367 | 1.430 |
Why?
|
Adverse Drug Reaction Reporting Systems | 10 | 2020 | 469 | 1.390 |
Why?
|
Drug Prescriptions | 11 | 2020 | 1637 | 1.360 |
Why?
|
Adamantane | 3 | 2017 | 173 | 1.160 |
Why?
|
Information Storage and Retrieval | 3 | 2022 | 824 | 1.150 |
Why?
|
Gastrointestinal Hemorrhage | 6 | 2023 | 1131 | 1.100 |
Why?
|
Models, Statistical | 9 | 2022 | 5101 | 1.090 |
Why?
|
Electronic Health Records | 22 | 2024 | 4468 | 1.080 |
Why?
|
Algorithms | 20 | 2024 | 13882 | 1.080 |
Why?
|
Dipeptides | 3 | 2017 | 409 | 1.080 |
Why?
|
Gastric Bypass | 8 | 2023 | 812 | 1.050 |
Why?
|
Sentinel Surveillance | 6 | 2018 | 281 | 1.030 |
Why?
|
Drug Therapy | 2 | 2019 | 497 | 0.980 |
Why?
|
Bariatric Surgery | 8 | 2022 | 952 | 0.960 |
Why?
|
Data Collection | 7 | 2020 | 3339 | 0.950 |
Why?
|
Drug Utilization | 5 | 2018 | 1183 | 0.950 |
Why?
|
Anti-Bacterial Agents | 13 | 2023 | 7182 | 0.930 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 3 | 2017 | 293 | 0.880 |
Why?
|
Medication Errors | 2 | 2019 | 798 | 0.880 |
Why?
|
Adrenergic beta-Antagonists | 3 | 2018 | 1240 | 0.870 |
Why?
|
Hypoglycemic Agents | 10 | 2023 | 2873 | 0.850 |
Why?
|
Insurance | 1 | 2023 | 111 | 0.840 |
Why?
|
Choledocholithiasis | 1 | 2022 | 48 | 0.810 |
Why?
|
Antidepressive Agents | 6 | 2019 | 2838 | 0.810 |
Why?
|
Cholecystitis, Acute | 1 | 2022 | 70 | 0.810 |
Why?
|
Pregnancy Complications | 8 | 2018 | 2861 | 0.790 |
Why?
|
Drug Labeling | 3 | 2019 | 233 | 0.790 |
Why?
|
Warfarin | 7 | 2023 | 1497 | 0.790 |
Why?
|
Cholangitis | 1 | 2022 | 108 | 0.780 |
Why?
|
Trazodone | 1 | 2020 | 66 | 0.760 |
Why?
|
Hydrochlorothiazide | 1 | 2021 | 98 | 0.760 |
Why?
|
Pharmaceutical Preparations | 6 | 2023 | 1070 | 0.730 |
Why?
|
Antihypertensive Agents | 3 | 2021 | 2047 | 0.730 |
Why?
|
Poisson Distribution | 4 | 2019 | 513 | 0.720 |
Why?
|
United States | 66 | 2023 | 69872 | 0.720 |
Why?
|
Obesity, Morbid | 6 | 2022 | 1213 | 0.710 |
Why?
|
Diabetes Mellitus, Type 2 | 11 | 2023 | 11726 | 0.710 |
Why?
|
Humans | 170 | 2024 | 744366 | 0.700 |
Why?
|
Incretins | 1 | 2019 | 88 | 0.670 |
Why?
|
Proportional Hazards Models | 17 | 2023 | 12356 | 0.670 |
Why?
|
Mefenamic Acid | 1 | 2018 | 5 | 0.650 |
Why?
|
Hypoglycemia | 2 | 2023 | 861 | 0.650 |
Why?
|
Cohort Studies | 36 | 2024 | 40559 | 0.650 |
Why?
|
Self-Injurious Behavior | 1 | 2023 | 464 | 0.630 |
Why?
|
Equipment and Supplies | 3 | 2020 | 281 | 0.630 |
Why?
|
Computer Communication Networks | 4 | 2023 | 295 | 0.620 |
Why?
|
Prescriptions | 5 | 2022 | 387 | 0.620 |
Why?
|
Diclofenac | 1 | 2018 | 71 | 0.610 |
Why?
|
Naproxen | 1 | 2018 | 99 | 0.610 |
Why?
|
Information Services | 1 | 2019 | 244 | 0.610 |
Why?
|
Morning Sickness | 1 | 2017 | 5 | 0.600 |
Why?
|
Drug Monitoring | 2 | 2014 | 956 | 0.600 |
Why?
|
National Health Programs | 1 | 2020 | 445 | 0.590 |
Why?
|
Statistics as Topic | 2 | 2014 | 2373 | 0.580 |
Why?
|
Niacin | 1 | 2017 | 116 | 0.580 |
Why?
|
Central Nervous System Stimulants | 3 | 2018 | 1148 | 0.570 |
Why?
|
Photosensitizing Agents | 1 | 2021 | 602 | 0.560 |
Why?
|
Influenza, Human | 4 | 2022 | 1479 | 0.560 |
Why?
|
Insurance Claim Review | 3 | 2020 | 720 | 0.560 |
Why?
|
Taiwan | 3 | 2023 | 496 | 0.560 |
Why?
|
Ondansetron | 1 | 2017 | 90 | 0.560 |
Why?
|
Ibuprofen | 1 | 2018 | 236 | 0.560 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2018 | 255 | 0.560 |
Why?
|
Gastrectomy | 7 | 2023 | 663 | 0.540 |
Why?
|
Prenatal Care | 3 | 2018 | 1092 | 0.540 |
Why?
|
Aortic Aneurysm | 1 | 2020 | 644 | 0.540 |
Why?
|
Risk Adjustment | 1 | 2019 | 594 | 0.540 |
Why?
|
Data Interpretation, Statistical | 6 | 2020 | 2716 | 0.530 |
Why?
|
Drug Approval | 7 | 2021 | 742 | 0.520 |
Why?
|
Antiemetics | 1 | 2017 | 177 | 0.520 |
Why?
|
Carcinoma, Basal Cell | 1 | 2021 | 545 | 0.520 |
Why?
|
Health Care Surveys | 4 | 2016 | 2453 | 0.500 |
Why?
|
Myocardial Infarction | 8 | 2022 | 11718 | 0.480 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 3 | 2018 | 2282 | 0.480 |
Why?
|
Cyclooxygenase 2 Inhibitors | 2 | 2018 | 320 | 0.470 |
Why?
|
Cardiovascular System | 2 | 2019 | 831 | 0.470 |
Why?
|
Pregnancy Trimesters | 4 | 2018 | 192 | 0.460 |
Why?
|
Female | 87 | 2023 | 380193 | 0.460 |
Why?
|
Antiviral Agents | 6 | 2022 | 2987 | 0.460 |
Why?
|
Software | 4 | 2017 | 4441 | 0.460 |
Why?
|
Aortic Valve | 1 | 2023 | 1924 | 0.460 |
Why?
|
Meta-Analysis as Topic | 2 | 2015 | 1342 | 0.460 |
Why?
|
Population Surveillance | 5 | 2018 | 2616 | 0.460 |
Why?
|
Pregnancy Trimester, First | 3 | 2019 | 853 | 0.460 |
Why?
|
Estrogen Replacement Therapy | 2 | 2010 | 1203 | 0.450 |
Why?
|
Pregnancy | 31 | 2022 | 29144 | 0.450 |
Why?
|
Computer Simulation | 10 | 2023 | 6194 | 0.440 |
Why?
|
Hypolipidemic Agents | 1 | 2017 | 604 | 0.440 |
Why?
|
Angiotensin Receptor Antagonists | 3 | 2013 | 923 | 0.430 |
Why?
|
Intracranial Hemorrhages | 2 | 2018 | 855 | 0.430 |
Why?
|
Pancreatitis | 1 | 2019 | 1092 | 0.430 |
Why?
|
Hyperlipidemias | 1 | 2017 | 789 | 0.430 |
Why?
|
Adult | 58 | 2023 | 214052 | 0.430 |
Why?
|
Medroxyprogesterone Acetate | 2 | 2010 | 163 | 0.430 |
Why?
|
Research Personnel | 1 | 2017 | 573 | 0.420 |
Why?
|
Anti-Asthmatic Agents | 4 | 2020 | 536 | 0.420 |
Why?
|
Glyburide | 3 | 2023 | 113 | 0.410 |
Why?
|
Selection Bias | 4 | 2022 | 371 | 0.410 |
Why?
|
Middle Aged | 56 | 2023 | 213390 | 0.410 |
Why?
|
Antirheumatic Agents | 3 | 2019 | 1338 | 0.410 |
Why?
|
Probability | 6 | 2023 | 2506 | 0.410 |
Why?
|
Young Adult | 36 | 2022 | 56429 | 0.410 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 4 | 2018 | 3658 | 0.400 |
Why?
|
Medical Informatics Applications | 1 | 2013 | 186 | 0.400 |
Why?
|
Regression Analysis | 4 | 2019 | 6459 | 0.400 |
Why?
|
Oseltamivir | 3 | 2022 | 75 | 0.390 |
Why?
|
Dopamine Uptake Inhibitors | 1 | 2013 | 312 | 0.390 |
Why?
|
Quinoxalines | 1 | 2013 | 290 | 0.390 |
Why?
|
Bupropion | 1 | 2013 | 303 | 0.390 |
Why?
|
Incidence | 12 | 2021 | 20952 | 0.390 |
Why?
|
Nicotinic Agonists | 1 | 2013 | 271 | 0.390 |
Why?
|
Anticoagulants | 5 | 2020 | 4600 | 0.390 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2022 | 2200 | 0.380 |
Why?
|
Benzazepines | 1 | 2013 | 326 | 0.380 |
Why?
|
Clindamycin | 2 | 2023 | 139 | 0.380 |
Why?
|
Outpatients | 1 | 2018 | 1487 | 0.370 |
Why?
|
Dementia | 3 | 2023 | 2518 | 0.370 |
Why?
|
Perinatal Care | 2 | 2013 | 227 | 0.360 |
Why?
|
Heart Failure | 3 | 2019 | 10895 | 0.360 |
Why?
|
Pregnancy, Unplanned | 1 | 2010 | 95 | 0.350 |
Why?
|
Adolescent | 33 | 2022 | 85779 | 0.340 |
Why?
|
Stroke | 7 | 2023 | 9981 | 0.340 |
Why?
|
Odds Ratio | 3 | 2019 | 9849 | 0.340 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2018 | 4424 | 0.340 |
Why?
|
Live Birth | 4 | 2022 | 512 | 0.330 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2010 | 275 | 0.320 |
Why?
|
Retrospective Studies | 34 | 2022 | 77460 | 0.320 |
Why?
|
Atrial Fibrillation | 5 | 2022 | 5035 | 0.320 |
Why?
|
Contraceptives, Oral | 1 | 2010 | 564 | 0.310 |
Why?
|
Renin-Angiotensin System | 1 | 2012 | 758 | 0.310 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2023 | 3255 | 0.310 |
Why?
|
Male | 51 | 2023 | 350115 | 0.310 |
Why?
|
Brain Ischemia | 1 | 2022 | 3265 | 0.310 |
Why?
|
Gestational Age | 3 | 2022 | 3493 | 0.310 |
Why?
|
Drug Utilization Review | 3 | 2018 | 245 | 0.310 |
Why?
|
Aged | 30 | 2022 | 163288 | 0.300 |
Why?
|
Biostatistics | 1 | 2008 | 161 | 0.290 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2019 | 3070 | 0.280 |
Why?
|
Pregnancy Outcome | 7 | 2014 | 2795 | 0.280 |
Why?
|
Cardiomyopathies | 1 | 2018 | 1912 | 0.280 |
Why?
|
Delivery of Health Care | 6 | 2024 | 5321 | 0.280 |
Why?
|
Prenatal Exposure Delayed Effects | 5 | 2019 | 2408 | 0.280 |
Why?
|
Prevalence | 11 | 2021 | 15221 | 0.280 |
Why?
|
Ambulatory Care | 2 | 2016 | 2708 | 0.280 |
Why?
|
Birth Certificates | 4 | 2013 | 67 | 0.270 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 2 | 2017 | 103 | 0.270 |
Why?
|
Antipsychotic Agents | 3 | 2019 | 3057 | 0.270 |
Why?
|
Fetal Growth Retardation | 1 | 2009 | 570 | 0.270 |
Why?
|
Risk Factors | 18 | 2021 | 72296 | 0.270 |
Why?
|
Suicide | 2 | 2018 | 1474 | 0.260 |
Why?
|
Sulfonylurea Compounds | 2 | 2017 | 205 | 0.260 |
Why?
|
Delivery, Obstetric | 1 | 2013 | 906 | 0.260 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2021 | 4034 | 0.250 |
Why?
|
Body Height | 2 | 2022 | 1578 | 0.250 |
Why?
|
Insulin, Long-Acting | 2 | 2017 | 57 | 0.250 |
Why?
|
Infant, Newborn | 14 | 2021 | 25628 | 0.240 |
Why?
|
Sulbactam | 1 | 2023 | 26 | 0.240 |
Why?
|
Depressive Disorder | 2 | 2019 | 3747 | 0.240 |
Why?
|
Amoxicillin-Potassium Clavulanate Combination | 1 | 2023 | 30 | 0.230 |
Why?
|
Logistic Models | 6 | 2020 | 13409 | 0.230 |
Why?
|
Ampicillin | 1 | 2023 | 139 | 0.230 |
Why?
|
Follow-Up Studies | 11 | 2020 | 39052 | 0.230 |
Why?
|
Thiazolidinediones | 2 | 2017 | 476 | 0.230 |
Why?
|
Body Mass Index | 8 | 2021 | 12721 | 0.230 |
Why?
|
Attitude of Health Personnel | 1 | 2017 | 3841 | 0.230 |
Why?
|
Fertilization | 2 | 2019 | 196 | 0.230 |
Why?
|
Medical Record Linkage | 4 | 2023 | 284 | 0.220 |
Why?
|
Consumer Product Safety | 2 | 2014 | 122 | 0.220 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2009 | 489 | 0.220 |
Why?
|
Mood Disorders | 1 | 2009 | 1106 | 0.220 |
Why?
|
Hospitalization | 8 | 2022 | 10259 | 0.220 |
Why?
|
Medicare | 2 | 2021 | 6566 | 0.220 |
Why?
|
Cephalosporins | 1 | 2023 | 204 | 0.220 |
Why?
|
Fumarates | 2 | 2013 | 132 | 0.210 |
Why?
|
Cardiovascular Diseases | 2 | 2022 | 15160 | 0.210 |
Why?
|
Neoplasms | 4 | 2021 | 21696 | 0.210 |
Why?
|
Medication Adherence | 2 | 2010 | 2063 | 0.200 |
Why?
|
Causality | 3 | 2024 | 1275 | 0.200 |
Why?
|
Aged, 80 and over | 12 | 2020 | 57776 | 0.200 |
Why?
|
Dementia, Vascular | 1 | 2023 | 129 | 0.200 |
Why?
|
Feasibility Studies | 3 | 2022 | 5077 | 0.200 |
Why?
|
Time Factors | 13 | 2020 | 40075 | 0.200 |
Why?
|
Drug Interactions | 2 | 2020 | 1460 | 0.200 |
Why?
|
Skin Neoplasms | 1 | 2021 | 5692 | 0.200 |
Why?
|
Insurance, Medigap | 1 | 2020 | 19 | 0.190 |
Why?
|
Smoking Cessation | 1 | 2013 | 2071 | 0.190 |
Why?
|
Postmenopause | 1 | 2010 | 2460 | 0.190 |
Why?
|
Endpoint Determination | 2 | 2014 | 601 | 0.190 |
Why?
|
Peptic Ulcer | 1 | 2022 | 223 | 0.190 |
Why?
|
Amides | 2 | 2013 | 459 | 0.180 |
Why?
|
Anti-Infective Agents | 1 | 2008 | 974 | 0.180 |
Why?
|
Intrauterine Devices, Medicated | 1 | 2020 | 28 | 0.180 |
Why?
|
Intrauterine Devices, Copper | 1 | 2020 | 32 | 0.180 |
Why?
|
Immunoglobulin G | 1 | 2012 | 4561 | 0.180 |
Why?
|
Child, Preschool | 13 | 2022 | 41005 | 0.180 |
Why?
|
Autoimmune Diseases | 1 | 2012 | 2134 | 0.180 |
Why?
|
Medical Records | 5 | 2020 | 1413 | 0.180 |
Why?
|
Case-Control Studies | 4 | 2020 | 21748 | 0.180 |
Why?
|
Antibodies, Monoclonal | 2 | 2018 | 9274 | 0.170 |
Why?
|
Multivariate Analysis | 3 | 2019 | 12244 | 0.170 |
Why?
|
Orphan Drug Production | 1 | 2020 | 50 | 0.170 |
Why?
|
Pain, Intractable | 1 | 2020 | 130 | 0.170 |
Why?
|
Brain Infarction | 2 | 2018 | 299 | 0.170 |
Why?
|
Government Regulation | 2 | 2014 | 522 | 0.170 |
Why?
|
Body Weight | 2 | 2021 | 4671 | 0.170 |
Why?
|
Stillbirth | 1 | 2022 | 346 | 0.170 |
Why?
|
Zanamivir | 1 | 2018 | 21 | 0.170 |
Why?
|
Reference Standards | 1 | 2022 | 1025 | 0.160 |
Why?
|
Risk Assessment | 10 | 2020 | 23336 | 0.160 |
Why?
|
Acute Disease | 3 | 2018 | 7147 | 0.160 |
Why?
|
Analgesics, Opioid | 3 | 2021 | 3677 | 0.160 |
Why?
|
Pregnancy in Diabetics | 1 | 2019 | 179 | 0.160 |
Why?
|
Neural Tube Defects | 1 | 2020 | 256 | 0.160 |
Why?
|
Canada | 2 | 2023 | 2065 | 0.160 |
Why?
|
Asthma | 4 | 2020 | 6010 | 0.160 |
Why?
|
Registries | 3 | 2018 | 8091 | 0.160 |
Why?
|
Anticonvulsants | 2 | 2022 | 1916 | 0.160 |
Why?
|
Diabetes, Gestational | 3 | 2019 | 1184 | 0.160 |
Why?
|
Health Benefit Plans, Employee | 1 | 2020 | 332 | 0.160 |
Why?
|
Off-Label Use | 1 | 2019 | 169 | 0.150 |
Why?
|
Age Factors | 4 | 2021 | 18373 | 0.150 |
Why?
|
Glipizide | 1 | 2017 | 47 | 0.150 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2018 | 113 | 0.150 |
Why?
|
Schizophrenia | 3 | 2019 | 6882 | 0.150 |
Why?
|
Premature Birth | 1 | 2009 | 1721 | 0.150 |
Why?
|
Fenofibrate | 1 | 2017 | 88 | 0.150 |
Why?
|
Gastroplasty | 2 | 2018 | 142 | 0.150 |
Why?
|
Spondylitis, Ankylosing | 1 | 2018 | 156 | 0.150 |
Why?
|
Child | 17 | 2022 | 77709 | 0.140 |
Why?
|
Suicidal Ideation | 2 | 2023 | 1246 | 0.140 |
Why?
|
Sodium | 1 | 2022 | 1622 | 0.140 |
Why?
|
Electronics | 3 | 2022 | 322 | 0.140 |
Why?
|
Legislation, Drug | 1 | 2018 | 206 | 0.140 |
Why?
|
Ultraviolet Rays | 1 | 2021 | 1060 | 0.130 |
Why?
|
Infant | 9 | 2022 | 35134 | 0.130 |
Why?
|
Trimethoprim | 1 | 2015 | 91 | 0.130 |
Why?
|
Arthritis, Psoriatic | 1 | 2018 | 215 | 0.130 |
Why?
|
Piperidines | 1 | 2024 | 1602 | 0.130 |
Why?
|
Pilot Projects | 6 | 2021 | 8319 | 0.130 |
Why?
|
Quinolines | 1 | 2020 | 732 | 0.130 |
Why?
|
Fractures, Bone | 1 | 2007 | 1947 | 0.130 |
Why?
|
Treatment Outcome | 11 | 2024 | 63107 | 0.130 |
Why?
|
Aromatase Inhibitors | 1 | 2019 | 490 | 0.130 |
Why?
|
Coronary Disease | 1 | 2010 | 6077 | 0.130 |
Why?
|
Rare Diseases | 1 | 2020 | 553 | 0.130 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2019 | 2026 | 0.120 |
Why?
|
Antithrombins | 1 | 2017 | 304 | 0.120 |
Why?
|
Pregnancy, Multiple | 2 | 2013 | 217 | 0.120 |
Why?
|
Weight Loss | 3 | 2022 | 2625 | 0.120 |
Why?
|
Delayed-Action Preparations | 1 | 2017 | 968 | 0.120 |
Why?
|
Drug Costs | 1 | 2021 | 1105 | 0.120 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2013 | 38 | 0.110 |
Why?
|
Research Subjects | 1 | 2015 | 239 | 0.110 |
Why?
|
Labor, Induced | 1 | 2014 | 146 | 0.110 |
Why?
|
Patient Readmission | 2 | 2017 | 3116 | 0.110 |
Why?
|
Patient Compliance | 2 | 2018 | 2684 | 0.110 |
Why?
|
Opioid-Related Disorders | 2 | 2021 | 2064 | 0.110 |
Why?
|
Hemorrhage | 3 | 2020 | 3461 | 0.110 |
Why?
|
Genital Neoplasms, Female | 1 | 2018 | 523 | 0.110 |
Why?
|
Linear Models | 2 | 2022 | 5953 | 0.110 |
Why?
|
Epidemiologic Methods | 2 | 2015 | 1364 | 0.110 |
Why?
|
Abnormalities, Drug-Induced | 1 | 2015 | 317 | 0.110 |
Why?
|
Evidence-Based Practice | 1 | 2017 | 501 | 0.110 |
Why?
|
Longitudinal Studies | 1 | 2008 | 13991 | 0.110 |
Why?
|
Predictive Value of Tests | 8 | 2020 | 15078 | 0.100 |
Why?
|
Depressive Disorder, Major | 3 | 2019 | 4639 | 0.100 |
Why?
|
Disease | 1 | 2017 | 680 | 0.100 |
Why?
|
Sex Factors | 3 | 2021 | 10400 | 0.100 |
Why?
|
Pyrimidines | 1 | 2024 | 2943 | 0.100 |
Why?
|
Health Policy | 3 | 2021 | 2661 | 0.100 |
Why?
|
Alzheimer Disease | 2 | 2023 | 8038 | 0.100 |
Why?
|
Colitis, Ulcerative | 1 | 2024 | 1911 | 0.100 |
Why?
|
Costs and Cost Analysis | 1 | 2017 | 1680 | 0.100 |
Why?
|
Anaphylaxis | 1 | 2018 | 746 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2022 | 9955 | 0.100 |
Why?
|
Demography | 2 | 2023 | 1655 | 0.100 |
Why?
|
Clostridium Infections | 1 | 2018 | 548 | 0.100 |
Why?
|
Cholesterol, HDL | 1 | 2017 | 1813 | 0.100 |
Why?
|
Perception | 1 | 2017 | 1198 | 0.090 |
Why?
|
Death, Sudden, Cardiac | 1 | 2019 | 1541 | 0.090 |
Why?
|
Monte Carlo Method | 2 | 2019 | 1254 | 0.090 |
Why?
|
Diabetes Mellitus | 2 | 2019 | 5749 | 0.090 |
Why?
|
Goals | 1 | 2015 | 707 | 0.090 |
Why?
|
Pneumonia | 1 | 2022 | 2133 | 0.090 |
Why?
|
Glucose | 1 | 2022 | 4398 | 0.090 |
Why?
|
Suicide, Attempted | 1 | 2018 | 1218 | 0.090 |
Why?
|
Crohn Disease | 1 | 2022 | 2304 | 0.090 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2013 | 387 | 0.090 |
Why?
|
Pre-Eclampsia | 2 | 2009 | 1200 | 0.090 |
Why?
|
Medical Records Systems, Computerized | 2 | 2013 | 1205 | 0.090 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2012 | 595 | 0.090 |
Why?
|
Overweight | 1 | 2020 | 2371 | 0.090 |
Why?
|
Insulin | 3 | 2023 | 6582 | 0.080 |
Why?
|
Comorbidity | 3 | 2018 | 10388 | 0.080 |
Why?
|
Prescription Drugs | 1 | 2016 | 595 | 0.080 |
Why?
|
Research Support as Topic | 1 | 2013 | 705 | 0.080 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2023 | 3338 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2021 | 10943 | 0.080 |
Why?
|
Mothers | 1 | 2019 | 2165 | 0.080 |
Why?
|
Breast Neoplasms | 2 | 2018 | 20824 | 0.080 |
Why?
|
Hypertension | 2 | 2018 | 8479 | 0.080 |
Why?
|
California | 1 | 2012 | 1402 | 0.080 |
Why?
|
Quality Assurance, Health Care | 2 | 2019 | 2212 | 0.080 |
Why?
|
Random Allocation | 2 | 2011 | 2428 | 0.080 |
Why?
|
Carcinoma in Situ | 1 | 2013 | 806 | 0.080 |
Why?
|
Patient-Centered Care | 3 | 2023 | 1438 | 0.070 |
Why?
|
Tobacco Use Disorder | 1 | 2013 | 688 | 0.070 |
Why?
|
Mortality | 1 | 2018 | 2864 | 0.070 |
Why?
|
Advisory Committees | 1 | 2011 | 775 | 0.070 |
Why?
|
Risk | 3 | 2018 | 9688 | 0.070 |
Why?
|
Maternal Exposure | 1 | 2013 | 961 | 0.070 |
Why?
|
Hematologic Neoplasms | 1 | 2018 | 1832 | 0.070 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2014 | 1320 | 0.070 |
Why?
|
Laparoscopy | 2 | 2018 | 2150 | 0.070 |
Why?
|
Venous Thromboembolism | 1 | 2018 | 1671 | 0.070 |
Why?
|
Sulfonamides | 1 | 2015 | 1940 | 0.070 |
Why?
|
Double-Blind Method | 2 | 2010 | 12025 | 0.070 |
Why?
|
Reproducibility of Results | 6 | 2019 | 19905 | 0.070 |
Why?
|
Acute Coronary Syndrome | 1 | 2019 | 2337 | 0.070 |
Why?
|
Drug Therapy, Combination | 2 | 2020 | 6489 | 0.070 |
Why?
|
Chronic Disease | 2 | 2018 | 9145 | 0.070 |
Why?
|
Program Development | 1 | 2012 | 1316 | 0.060 |
Why?
|
Thyroid Neoplasms | 1 | 2018 | 2282 | 0.060 |
Why?
|
Prospective Studies | 6 | 2023 | 53290 | 0.060 |
Why?
|
Cross-Over Studies | 1 | 2010 | 2029 | 0.060 |
Why?
|
Women's Health | 1 | 2014 | 2034 | 0.060 |
Why?
|
Liver Diseases | 1 | 2013 | 1253 | 0.060 |
Why?
|
Postoperative Complications | 4 | 2020 | 15297 | 0.060 |
Why?
|
Treatment Failure | 1 | 2010 | 2618 | 0.060 |
Why?
|
Genetic Testing | 1 | 2017 | 3444 | 0.060 |
Why?
|
Confidence Intervals | 1 | 2010 | 2971 | 0.060 |
Why?
|
Hyperglycemia | 1 | 2013 | 1373 | 0.060 |
Why?
|
Guideline Adherence | 1 | 2014 | 2265 | 0.060 |
Why?
|
Estrogens | 1 | 2010 | 1566 | 0.060 |
Why?
|
Insurance Coverage | 1 | 2014 | 1900 | 0.060 |
Why?
|
Arthritis, Rheumatoid | 1 | 2018 | 3712 | 0.060 |
Why?
|
Fetal Development | 1 | 2009 | 767 | 0.060 |
Why?
|
Lung Neoplasms | 1 | 2007 | 13104 | 0.050 |
Why?
|
Administration, Oral | 2 | 2021 | 3914 | 0.050 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 3047 | 0.050 |
Why?
|
Immunologic Factors | 1 | 2012 | 1580 | 0.050 |
Why?
|
Laxatives | 1 | 2023 | 87 | 0.050 |
Why?
|
Socioeconomic Factors | 2 | 2013 | 7785 | 0.050 |
Why?
|
Models, Structural | 1 | 2022 | 361 | 0.050 |
Why?
|
Maternal Age | 2 | 2016 | 802 | 0.050 |
Why?
|
Biomedical Research | 2 | 2020 | 3309 | 0.050 |
Why?
|
Genomics | 1 | 2017 | 5717 | 0.050 |
Why?
|
Carbamazepine | 1 | 2022 | 229 | 0.050 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2013 | 2020 | 0.050 |
Why?
|
Oxymorphone | 1 | 2020 | 7 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2013 | 14723 | 0.050 |
Why?
|
Melanoma | 1 | 2018 | 5511 | 0.040 |
Why?
|
Levonorgestrel | 1 | 2020 | 77 | 0.040 |
Why?
|
Filgrastim | 1 | 2019 | 133 | 0.040 |
Why?
|
Insurance, Health | 1 | 2012 | 2494 | 0.040 |
Why?
|
Hematologic Agents | 1 | 2019 | 39 | 0.040 |
Why?
|
Sulfides | 1 | 2020 | 165 | 0.040 |
Why?
|
Decision Making, Organizational | 1 | 2020 | 139 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6539 | 0.040 |
Why?
|
Valproic Acid | 1 | 2022 | 445 | 0.040 |
Why?
|
Disease-Free Survival | 1 | 2010 | 6896 | 0.040 |
Why?
|
Acetates | 1 | 2020 | 311 | 0.040 |
Why?
|
Insulin Resistance | 1 | 2013 | 3864 | 0.040 |
Why?
|
Cyclopropanes | 1 | 2020 | 416 | 0.040 |
Why?
|
Pain | 1 | 2014 | 4988 | 0.040 |
Why?
|
Decision Making | 3 | 2020 | 3888 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13693 | 0.040 |
Why?
|
Oxycodone | 1 | 2020 | 153 | 0.040 |
Why?
|
Insemination, Artificial | 1 | 2019 | 98 | 0.040 |
Why?
|
Necrosis | 1 | 2022 | 1643 | 0.040 |
Why?
|
Constipation | 1 | 2023 | 546 | 0.040 |
Why?
|
Biological Specimen Banks | 1 | 2023 | 711 | 0.040 |
Why?
|
Capital Financing | 1 | 2017 | 58 | 0.040 |
Why?
|
Epilepsy | 1 | 2012 | 3310 | 0.040 |
Why?
|
Fertility | 1 | 2022 | 781 | 0.040 |
Why?
|
Natural Language Processing | 1 | 2024 | 1041 | 0.030 |
Why?
|
Recurrence | 2 | 2022 | 8340 | 0.030 |
Why?
|
Health Status | 1 | 2009 | 4034 | 0.030 |
Why?
|
Administration, Inhalation | 1 | 2017 | 1105 | 0.030 |
Why?
|
Drug and Narcotic Control | 1 | 2015 | 146 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2022 | 25039 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2021 | 856 | 0.030 |
Why?
|
HIV Infections | 1 | 2020 | 16715 | 0.030 |
Why?
|
Blood Pressure | 1 | 2009 | 8551 | 0.030 |
Why?
|
HIV | 1 | 2020 | 1604 | 0.030 |
Why?
|
Risk-Taking | 1 | 2018 | 986 | 0.030 |
Why?
|
Obstetric Labor Complications | 1 | 2014 | 238 | 0.030 |
Why?
|
Drug Combinations | 1 | 2017 | 1958 | 0.030 |
Why?
|
Weight Gain | 1 | 2022 | 2293 | 0.020 |
Why?
|
Postpartum Period | 1 | 2018 | 1086 | 0.020 |
Why?
|
Fertilization in Vitro | 1 | 2019 | 1284 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4933 | 0.020 |
Why?
|
Pregnancy Trimester, Third | 1 | 2013 | 571 | 0.020 |
Why?
|
Pregnancy Trimester, Second | 1 | 2013 | 732 | 0.020 |
Why?
|
Oxygen | 1 | 2021 | 4189 | 0.020 |
Why?
|
History, 21st Century | 1 | 2015 | 1534 | 0.020 |
Why?
|
Epidemiology | 1 | 2011 | 287 | 0.020 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2013 | 370 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2017 | 2108 | 0.020 |
Why?
|
Data Mining | 1 | 2013 | 537 | 0.020 |
Why?
|
Medicaid | 1 | 2021 | 2737 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2017 | 15535 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3508 | 0.020 |
Why?
|
Infertility, Female | 1 | 2013 | 788 | 0.020 |
Why?
|
Specialization | 1 | 2011 | 776 | 0.020 |
Why?
|
Health Behavior | 1 | 2018 | 2635 | 0.020 |
Why?
|
Sweden | 1 | 2009 | 1341 | 0.020 |
Why?
|
Parity | 1 | 2009 | 929 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2014 | 941 | 0.020 |
Why?
|
Metformin | 1 | 2013 | 836 | 0.020 |
Why?
|
Gynecology | 1 | 2011 | 513 | 0.020 |
Why?
|
Health Services Research | 1 | 2013 | 1836 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2012 | 1504 | 0.020 |
Why?
|
Patient Discharge | 1 | 2017 | 3318 | 0.020 |
Why?
|
Obstetrics | 1 | 2011 | 658 | 0.020 |
Why?
|
Obesity | 2 | 2020 | 12746 | 0.020 |
Why?
|
Program Evaluation | 1 | 2012 | 2488 | 0.010 |
Why?
|
Biological Products | 1 | 2012 | 860 | 0.010 |
Why?
|
Depression | 1 | 2022 | 7759 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8385 | 0.010 |
Why?
|
Survival Rate | 1 | 2014 | 12788 | 0.010 |
Why?
|
Quality Improvement | 1 | 2014 | 3749 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2017 | 7658 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2014 | 7282 | 0.010 |
Why?
|
Animals | 1 | 2007 | 168768 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2011 | 5263 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2011 | 11126 | 0.000 |
Why?
|